BR112013032456A2 - anticorpo anti-cxcr4 com funções efetuadoras e seu uso para o tratamento de câncer - Google Patents

anticorpo anti-cxcr4 com funções efetuadoras e seu uso para o tratamento de câncer

Info

Publication number
BR112013032456A2
BR112013032456A2 BR112013032456A BR112013032456A BR112013032456A2 BR 112013032456 A2 BR112013032456 A2 BR 112013032456A2 BR 112013032456 A BR112013032456 A BR 112013032456A BR 112013032456 A BR112013032456 A BR 112013032456A BR 112013032456 A2 BR112013032456 A2 BR 112013032456A2
Authority
BR
Brazil
Prior art keywords
cancer treatment
effector functions
cxcr4 antibody
cxcr4
administering
Prior art date
Application number
BR112013032456A
Other languages
English (en)
Inventor
Christine Klinguerhamour
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of BR112013032456A2 publication Critical patent/BR112013032456A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

abstract the present application relates to a method of treating cancer by administering an anti-cxcr4 monoclonal antibody capable of inducing effector function(s). tradução do resumo resumo patente de invenção: "anticorpo anti-cxcr4 com funções efetuadoras e seu uso para o tratamento de câncer". o presente pedido se refere a um método de tratamento de câncer por administração de um anticorpo monoclonal anti-cxcr4 capaz de induzir função(ões) efetuadora(s).
BR112013032456A 2011-06-20 2012-06-20 anticorpo anti-cxcr4 com funções efetuadoras e seu uso para o tratamento de câncer BR112013032456A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161499004P 2011-06-20 2011-06-20
EP11305773 2011-06-20
PCT/EP2012/061893 WO2012175576A1 (en) 2011-06-20 2012-06-20 Anti-cxcr4 antibody with effector functions and its use for the treatment of cancer.

Publications (1)

Publication Number Publication Date
BR112013032456A2 true BR112013032456A2 (pt) 2016-11-22

Family

ID=44718440

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013032456A BR112013032456A2 (pt) 2011-06-20 2012-06-20 anticorpo anti-cxcr4 com funções efetuadoras e seu uso para o tratamento de câncer

Country Status (13)

Country Link
US (1) US20140120555A1 (pt)
EP (1) EP2721069A1 (pt)
JP (1) JP6223966B2 (pt)
KR (1) KR20140041698A (pt)
CN (1) CN103649120A (pt)
AR (1) AR086984A1 (pt)
AU (1) AU2012274104B2 (pt)
BR (1) BR112013032456A2 (pt)
CA (1) CA2838484A1 (pt)
MA (1) MA35173B1 (pt)
MX (1) MX2013015061A (pt)
RU (1) RU2013158624A (pt)
WO (1) WO2012175576A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201600171SA (en) * 2013-08-02 2016-02-26 Pfizer Anti-cxcr4 antibodies and antibody-drug conjugates
TW201718851A (zh) * 2015-09-18 2017-06-01 通用醫院公司 具有抗化學排斥(anti-fugetactic)性質之經修飾自然殺手細胞及其用途
WO2017049238A1 (en) * 2015-09-18 2017-03-23 The General Hospital Corporation Dba Massachusetts General Hospital Modified t-cells having anti-fugetactic properties and uses thereof
EP3471754A1 (en) 2016-06-20 2019-04-24 Kymab Limited Anti-pd-l1 antibodies
JP2021517588A (ja) * 2018-03-13 2021-07-26 フンダシオン・パラ・ラ・インベスティガシオン・ビオメディカ・デル・オスピタル・ウニベルシタリオ・ラ・パスＦｕｎｄａｃｉｏｎ Ｐａｒａ Ｌａ Ｉｎｖｅｓｔｉｇａｃｉｏｎ Ｂｉｏｍｅｄｉｃａ Ｄｅｌ Ｈｏｓｐｉｔａｌ Ｕｎｉｖｅｒｓｉｔａｒｉｏ Ｌａ Ｐａｚ 癌免疫療法のための活性化および拡張ナチュラルキラー細胞と組み合わせた抗ｃｘｃｒ４抗体
CN111918873A (zh) 2018-03-27 2020-11-10 百时美施贵宝公司 使用紫外线信号实时监测滴度
WO2020172658A1 (en) 2019-02-24 2020-08-27 Bristol-Myers Squibb Company Methods of isolating a protein
WO2020237221A1 (en) 2019-05-23 2020-11-26 Bristol-Myers Squibb Company Methods of monitoring cell culture media
JP2023544410A (ja) 2020-10-05 2023-10-23 ブリストル－マイヤーズ スクイブ カンパニー タンパク質を濃縮するための方法
WO2023173011A1 (en) 2022-03-09 2023-09-14 Bristol-Myers Squibb Company Transient expression of therapeutic proteins

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
GB8924581D0 (en) 1989-11-01 1989-12-20 Pa Consulting Services Bleaching of hair
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
AU633698B2 (en) 1990-01-12 1993-02-04 Amgen Fremont Inc. Generation of xenogeneic antibodies
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
EP1978033A3 (en) 1995-04-27 2008-12-24 Amgen Fremont Inc. Human antibodies derived from immunized xenomice
CA2219486A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
US6420140B1 (en) 1996-10-11 2002-07-16 Abgenix, Inc. Production of multimeric protein by cell fusion method
CA2616914C (en) 1996-12-03 2012-05-29 Abgenix, Inc. Egfr-binding antibody
CZ294425B6 (cs) 1997-04-14 2005-01-12 Micromet Ag Způsob výroby anti-humánního antigenového receptoru, anti-humánní antigenový receptor, řetězec VH a VL, souprava pro selekci anti-humánních antigenových receptorů a farmaceutická kompozice, obsahující uvedený receptor
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
ES2571230T3 (es) * 1999-04-09 2016-05-24 Kyowa Hakko Kirin Co Ltd Procedimiento para controlar la actividad de una molécula inmunofuncional
AU2002337935B2 (en) * 2001-10-25 2008-05-01 Genentech, Inc. Glycoprotein compositions
US20050002939A1 (en) 2002-12-23 2005-01-06 Albert Zlotnik Tumor killing/tumor regression using CXCR4 antagonists
TWI397536B (zh) 2005-07-22 2013-06-01 基因重組之抗體組成物
EP1878747A1 (en) 2006-07-11 2008-01-16 greenovation Biotech GmbH Glyco-engineered antibodies
ES2625798T3 (es) * 2006-10-02 2017-07-20 E. R. Squibb & Sons, L.L.C. Anticuerpos humanos que se unen a CXCR4 y usos de los mismos
JP2011520885A (ja) * 2008-05-14 2011-07-21 イーライ リリー アンド カンパニー 抗ｃｘｃｒ４抗体
EP2172485A1 (en) 2008-10-01 2010-04-07 Pierre Fabre Medicament Novel anti CXCR4 antibodies and their use for the treatment of cancer
EP2246364A1 (en) * 2009-04-29 2010-11-03 Pierre Fabre Médicament Anti CXCR4 antibodies for the treatment of HIV
EP2371863A1 (en) * 2010-03-30 2011-10-05 Pierre Fabre Médicament Humanized anti CXCR4 antibodies for the treatment of cancer

Also Published As

Publication number Publication date
CN103649120A (zh) 2014-03-19
US20140120555A1 (en) 2014-05-01
NZ618655A (en) 2015-09-25
AR086984A1 (es) 2014-02-05
WO2012175576A1 (en) 2012-12-27
AU2012274104A1 (en) 2014-01-09
MA35173B1 (fr) 2014-06-02
CA2838484A1 (en) 2012-12-27
RU2013158624A (ru) 2015-07-27
MX2013015061A (es) 2014-07-30
AU2012274104B2 (en) 2017-06-15
KR20140041698A (ko) 2014-04-04
EP2721069A1 (en) 2014-04-23
JP2014525899A (ja) 2014-10-02
JP6223966B2 (ja) 2017-11-01

Similar Documents

Publication Publication Date Title
BR112013032456A2 (pt) anticorpo anti-cxcr4 com funções efetuadoras e seu uso para o tratamento de câncer
CY1120398T1 (el) Ανθρωποποιημενα αντισωματα που αναγνωριζουν αλφα-συνουκλεϊνη
BR112016005816A2 (pt) Combinação de anticorpos anti-lag-3 e anticorpos anti-pd-1 para tratar tumores
BR112013029330A8 (pt) uso de anticorpo imunoconjugado maytansinoide anti-cd19 para o tratamento de sintomas de doenças de célula-b
NI201200171A (es) Anticuerpos hacia gdf8 humano
CL2017002283A1 (es) Formulaciones de anticuerpos y métodos (divisional de solicitud n°1081-2014)
AR059922A1 (es) Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
BR112015020911A2 (pt) anticorpo, uso de uma combinação e método de tratamento
AR101740A1 (es) Terapia de combinación y composiciones
EA201500265A1 (ru) Ингибиторы репликации вирусов гриппа
BR112013002484A2 (pt) composto, composição farmacêutica, métodos para tratar esclerose múltipla e artrite reumatoide, e, uso de um composto.
EA201491011A1 (ru) Способы лечения с помощью ингибитора гамма-интерферона
EA201690754A1 (ru) Применение ингибитора pcsk9 для лечения гиперлипидемии
BR112015025709A2 (pt) monoterapia com gla para uso em tratamento de câncer
TN2015000050A1 (en) Methods of treating a tauopathy
BR112016002287A2 (pt) compostos terapeuticamente ativos e seus métodos de uso
AR097178A1 (es) Diagnóstico y terapias anticáncer que comprenden células madre cancerosas
BR112015030356A2 (pt) métodos de tratamento de uma taupatia
TR201905101T4 (tr) Doku faktörü yolak inhibitörüne (TFPI) karşı monoklonal antikorlar.
BR112013029999A2 (pt) derivados de tiazol
BR112014000181A2 (pt) bloqueamento de anticorpo agr2 e uso dos mesmos
EA202091676A1 (ru) Способ лечения потери костной массы альвеолярного отростка посредством применения антител к склеростину
BR112014002140A2 (pt) anticorpo anti-cxcr4 e uso do mesmo para a detecção e o diagnóstico de câncer
MX361458B (es) Compuestos de pirimido-piridazinona y uso de los mismos.
BR112013024974A2 (pt) composto, composição farmacêutica, método para o tratamento de infecções virais, e, processo para preparar um composto

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2519 DE 16-04-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.